-+ 0.00%
-+ 0.00%
-+ 0.00%

CAMP4 Therapeutics Enters Into Strategic Research, Collaboration And License Agreement With GSK To Identify, Develop ASO Drug Candidates For Multiple Gene Targets Relevant To Neurodegenerative And Kidney Disease Indications

Benzinga·12/18/2025 12:03:01
Listen to the news
Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseasesCAMP4 to receive $17.5 million upfront and eligible for

Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases

CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments, in addition to tiered royalties

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, has entered into a strategic research, collaboration and license agreement with GSK to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.